Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 10.8%

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,130,000 shares, a decline of 10.8% from the January 15th total of 3,510,000 shares. Approximately 1.2% of the company's shares are sold short. Based on an average daily volume of 1,030,000 shares, the short-interest ratio is presently 3.0 days.

Grifols Stock Performance

Shares of GRFS traded down $0.08 during mid-day trading on Friday, reaching $7.45. The company had a trading volume of 562,369 shares, compared to its average volume of 774,833. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm has a 50-day moving average price of $7.38 and a 200 day moving average price of $8.08. Grifols has a 52 week low of $5.30 and a 52 week high of $9.96.

Hedge Funds Weigh In On Grifols

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GRFS. Soleus Capital Management L.P. lifted its position in Grifols by 46.1% in the 4th quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company's stock valued at $49,144,000 after acquiring an additional 2,083,722 shares in the last quarter. Norges Bank bought a new position in shares of Grifols during the 4th quarter valued at $14,434,000. Whitebox Advisors LLC lifted its holdings in shares of Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company's stock valued at $37,487,000 after buying an additional 1,519,093 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company's stock valued at $17,782,000 after buying an additional 1,181,959 shares during the period. Finally, Anthracite Investment Company Inc. bought a new position in shares of Grifols during the 3rd quarter valued at $5,457,000.

Wall Street Analyst Weigh In

GRFS has been the topic of a number of research analyst reports. Berenberg Bank upgraded Grifols to a "strong-buy" rating in a report on Tuesday, October 29th. Morgan Stanley assumed coverage on Grifols in a research report on Wednesday, February 12th. They issued an "overweight" rating on the stock.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.